Acne Skin Care

Skin Acne News

Obagi Medical Products' Fourth Quarter 2009 Revenue Increased 21% and Net Income More Than Doubled to $4.8 MillionThursday, March 11, 2010 @ 1:10PMLONG BEACH, Calif.----Obagi Medical Products, Inc. today reported net revenue for the fourth quarter ended December 31, 2009 rose 21% to $30.7 million, from $25.4 million in the fourth quarter of 2008.

Helix BioMedix Expands Skin Care Product Distribution into Key Asian Markets through Agreement with RubyDerm Bio, Inc.Thursday, March 11, 2010 @ 4:05AMBOTHELL, Wash.----Helix BioMedix, Inc. , a developer of bioactive peptides, announced that the Company entered into an agreement with RubyDerm Bio, Inc. under which RubyDerm will assume responsibility, on an exclusive basis, for the distribution of certain of Helix BioMedix’s branded prestige skin care products to spas, beauty stores, hospitals, clinics, physicians, and consumers in South Korea ...

Aggregate revenue of Safeguard Scientifics' partner companies for 2009 rises by 46%Thursday, March 11, 2010 @ 3:57AMSafeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that aggregate revenue of its partner companies for the year was $262 million, up 46% from $179 million in 2008, exceeding the company’s 2009 guidance of $223 million to $243 million, as adjusted to reflect the inclusion of two new partner companies.

Safeguard Scientifics Announces Fourth Quarter and Year-End 2009 Financial ResultsThursday, March 11, 2010 @ 3:00AMWAYNE, Pa.----Safeguard Scientifics, Inc. , a holding company that builds value in growth-stage life sciences and technology companies, today announced that aggregate revenue of its partner companies for the year was $262 million, up 46% from $179 million in 2008, exceeding the company’s 2009 guidance of $223 million to $243 million, as adjusted to reflect the inclusion of two new partner ...

NeuroSearch's MermaiHD study supports potential Huntington's disease modifying properties of HuntexilWednesday, March 10, 2010 @ 9:27PMNeuroSearch today announced that further analysis of the data from the MermaiHD study with Huntexil(R) (pridopidine) for the treatment of Huntington's disease supports potential disease modifying properties of the drug.